83 related articles for article (PubMed ID: 3066515)
1. Plasmid "curing" by some recently synthetized 4-quinolone compounds.
Selan L; Scazzocchio F; Oliva B; Schippa S; Allocati N; Renzini G
Chemioterapia; 1988 Oct; 7(5):292-4. PubMed ID: 3066515
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of plasmid conjugation by some recently synthetized 4-quinolone compounds.
Scazzocchio F; Selan L; Oliva B; Schippa S; Cellini L; Renzini G
Chemioterapia; 1988 Oct; 7(5):295-7. PubMed ID: 3066516
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of pefloxacin compared with five other quinolones on nalidixic acid-resistant proteae species.
Piccolomini R; Cellini L; Allocati N; Di Girolamo A; Selan L; Scazzocchio F
Chemioterapia; 1988 Oct; 7(5):287-91. PubMed ID: 3224396
[TBL] [Abstract][Full Text] [Related]
4. Biphasic kinetics of bacterial killing by quinolones.
Carret G; Flandrois JP; Lobry JR
J Antimicrob Chemother; 1991 Mar; 27(3):319-27. PubMed ID: 2037537
[TBL] [Abstract][Full Text] [Related]
5. [Comparative activities in vitro of 4 quinolones (nalidixic acid, pefloxacin, norfloxacin, ofloxacin) on 13 bacterial species].
Rahal K
Arch Inst Pasteur Alger; 1992; 58():41-84. PubMed ID: 1309146
[TBL] [Abstract][Full Text] [Related]
6. [Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins].
Croize J; Le Noc P; Bryskier A; Robert J
Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):564-8. PubMed ID: 3937128
[TBL] [Abstract][Full Text] [Related]
7. Elimination of plasmids by new 4-quinolones.
Weisser J; Wiedemann B
Antimicrob Agents Chemother; 1985 Nov; 28(5):700-2. PubMed ID: 3911881
[TBL] [Abstract][Full Text] [Related]
8. Determination of MICs for staphylococci using the API ATB quinolone and API ATB macrolide systems.
Rohner P; Peyret M; Auckenthaler R
Pathol Biol (Paris); 1993 Apr; 41(4):323-8. PubMed ID: 8233630
[TBL] [Abstract][Full Text] [Related]
9. In vivo selection during ofloxacin therapy of Escherichia coli with combined topoisomerase mutations that confer high resistance to ofloxacin but susceptibility to nalidixic acid.
Cattoir V; Lesprit P; Lascols C; Denamur E; Legrand P; Soussy CJ; Cambau E
J Antimicrob Chemother; 2006 Nov; 58(5):1054-7. PubMed ID: 16984897
[TBL] [Abstract][Full Text] [Related]
10. The effects of cannabispiro compounds and tetrahydrocannabidiolic acid on the plasmid transfer and maintenance in Escherichia coli.
Molnár J; Csiszár K; Nishioka I; Shoyama Y
Acta Microbiol Hung; 1986; 33(3):221-31. PubMed ID: 3551476
[TBL] [Abstract][Full Text] [Related]
11. [Comparative in vitro study of the activity of 5 quinolones against Acinetobacter calcoaceticus].
Joly-Guillou ML; Bergogne-Berezin E
Pathol Biol (Paris); 1985 May; 33(5):416-20. PubMed ID: 3162142
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of pefloxacin compared to that of quinolones and other antimicrobial agents.
Neu HC; Chin NX; Labthavikul P; Saha G
Chemioterapia; 1984 Aug; 3(4):235-41. PubMed ID: 6241847
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of the in vitro activity of 6 quinolones on Pseudomonas sp].
Lesage D; Delisle-Mizon F; Vergez P; Daguet GL
Pathol Biol (Paris); 1985 May; 33(5):412-5. PubMed ID: 3162141
[TBL] [Abstract][Full Text] [Related]
14. Ofloxacin: antibacterial activity, induction of resistance and killing curves.
Husson MO; Izard D; Bryskier A; Leclerc H
Chemioterapia; 1985 Aug; 4(4):278-83. PubMed ID: 3863716
[TBL] [Abstract][Full Text] [Related]
15. Biological activity of new aza analogues of quinolones.
Belicová A; Seman M; Milata V; Ilavský D; Ebringer L
Folia Microbiol (Praha); 1997; 42(3):193-8. PubMed ID: 9246761
[TBL] [Abstract][Full Text] [Related]
16. [Effect ofloxacin on Haemophilus influenza, Streptococcus pneumoniae and Neisseria meningitidis. Comparison with similar molecules].
Dabernat H; Delmas C; Lareng MB
Pathol Biol (Paris); 1985 May; 33(5):385-8. PubMed ID: 3162140
[TBL] [Abstract][Full Text] [Related]
17. Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe.
Mammeri H; Van De Loo M; Poirel L; Martinez-Martinez L; Nordmann P
Antimicrob Agents Chemother; 2005 Jan; 49(1):71-6. PubMed ID: 15616277
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of pefloxacin activity against recent clinical isolates.
Lembo M; Covelli B; Nani E; Lavitola A
J Chemother; 1991 Jan; 3 Suppl 1():51-3. PubMed ID: 12041785
[TBL] [Abstract][Full Text] [Related]
19. [Sensitivity of obligate anaerobes to ofloxacin, pefloxacin, enoxacin and norfloxacin].
Dubreuil L; Devos J; Romond C; Bryskier A
Pathol Biol (Paris); 1985 May; 33(5):421-5. PubMed ID: 3162143
[TBL] [Abstract][Full Text] [Related]
20. [Growing incidence of nalidixic acid resistance and sensitivity to quinolones in Salmonella typhimurium strains isolated from man or animal].
Heurtin-Le Corre C; Donnio PY; Bonnier M; Travert MF; Lacourt A; Avril JL
Pathol Biol (Paris); 1998 Oct; 46(8):587-90. PubMed ID: 9871929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
